Search

EHA Friends' Fund

Together, we can change the lives of many and make greater strides in the treatment of patients with blood disorders.

Read more

Expert opinions for COVID-19 vaccination in patients with hematologic cancer

Ronja Brockhoff, Hamdi Akan, Rafael Duarte, Martin Hönigl, Nikolay Klimko, Sibylle C. Mellinghoff, Livio Pagano, Antonio Pagliuca, Paul Verweij, Oliver A.

Read more

Commonalities and Differences in Myeloid Malignancies: Insights from the EHA-SWG Scientific Meeting on MDS, MPN, and AML

November 2-4 - Budapest, Hungary

Meeting Chairs:

Konstanze Döhner, University Hospital Ulm, Germany
Claire Harrison, Guy's and St.

Read more

Brussels Declaration on the Recognition of Professional QualificationsThe future of the Harmonisation of the Haematology Curriculum in Europe

On the occasion of the meeting, there was unanimous support for the

“Brussels Declaration on the Recognition of Professional Qualifications” that follows:

The mobility of haematology trainees is of the utmost importance.

Read more

EHA-PTHiT Mini Hematology Tutorial

EHA and the Polish Society of Hematology and Transfusion (PTHiT) are happy to present the second virtual 'mini Tutorial'. This two-day meeting aims to assess and increase your knowledge of the treatment of myeloid and lymphoid diseases.

Read more

EU projects

Creating a better world requires teamwork, partnerships, and collaboration. #bigdataforbloodcancer: Accelerating Better and Faster Treatment for Patients with Hematologic Malignancies.

Read more

In Memoriam Jean Claude Brouet

Professor Jean Claude Brouet passed away on December 12, 2022 at the age of 80.

Read more

The European Union must deliver funding for research of blood disorders

At the 20th Annual Congress of EHA, the results of two major projects are presented. The first is a study into the Cost of Blood Disorders in the EU Member States and Norway, Iceland, and Switzerland.

Read more

EHA-ECL led statement calls for protection of the Hospital Exemption

The hospital exemption (HE) is a vital provision within the EU's pharmaceutical legislation, currently subject to a revision.

Read more